Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.
作者信息
Dhand Abhay, Lobo Stephen A, Wolfe Kevin, Feola Nicholas, Nabors Christopher
机构信息
Department of Medicine, Westchester Medical Center, NY, USA.
Department of Surgery, Westchester Medical Center, NY, USA.
出版信息
Clin Transplant. 2021 Apr;35(4):e14245. doi: 10.1111/ctr.14245. Epub 2021 Feb 17.
Abstract
摘要
相似文献
1
Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.巴瑞替尼用于实体器官移植受者治疗新冠病毒病：单中心早期经验
Clin Transplant. 2021 Apr;35(4):e14245. doi: 10.1111/ctr.14245. Epub 2021 Feb 17.
2
A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.包括使用巴瑞替尼单抗或卡西瑞韦单抗-依德维单抗在内的程序化应对措施可降低新冠病毒检测呈阳性的腹部移植受者的住院率和死亡率。
Transplantation. 2022 Feb 1;106(2):e153-e157. doi: 10.1097/TP.0000000000003953.
3
Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience.卡西瑞维单抗-英夫西单抗用于实体器官移植受者治疗COVID-19：早期经验
Transplantation. 2021 Jul 1;105(7):e68-e69. doi: 10.1097/TP.0000000000003737.
4
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.COVID-19 于实体器官移植受者：来自美国震中地区的初步报告。
Am J Transplant. 2020 Jul;20(7):1800-1808. doi: 10.1111/ajt.15941. Epub 2020 May 10.
5
Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.实体器官移植受者使用巴利昔单抗单药治疗的初步经验。
Transpl Infect Dis. 2021 Oct;23(5):e13662. doi: 10.1111/tid.13662. Epub 2021 Jun 16.
6
Sotrovimab for Treatment of COVID-19 in Solid Organ Transplant Recipients.索托维单抗用于实体器官移植受者的新冠治疗
Transplantation. 2022 Jul 1;106(7):e336-e337. doi: 10.1097/TP.0000000000004136. Epub 2022 Apr 15.
7
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.贝特洛维单抗和索特罗维单抗治疗奥密克戎纪元中 COVID-19 轻症至中症的实体器官移植受者的结局。
Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25.
8
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.奥密克戎变异株流行期间，实体器官移植受者中可获得的门诊 COVID-19 治疗的真实世界经验。
Am J Transplant. 2022 Oct;22(10):2458-2463. doi: 10.1111/ajt.17098. Epub 2022 May 30.
9
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience.索托维单抗治疗实体器官移植患者早期轻/中度严重急性呼吸综合征冠状病毒2感染：单中心经验
Transplantation. 2022 Jul 1;106(7):e343-e345. doi: 10.1097/TP.0000000000004150. Epub 2022 Mar 24.
10
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.在单独接受巴利昔单抗或联合接受巴利昔单抗和埃特司韦单抗治疗的 COVID-19 轻症或中症患者中，针对 SARS-CoV-2 的内源性抗体反应。
Front Immunol. 2021 Dec 9;12:790469. doi: 10.3389/fimmu.2021.790469. eCollection 2021.
引用本文的文献
1
Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.索托维单抗用于 COVID-19 实体器官移植受者：一项系统评价和荟萃分析。
Korean J Transplant. 2023 Dec 31;37(4):277-285. doi: 10.4285/kjt.23.0038. Epub 2023 Nov 3.
2
The Treatment of COVID-19 With Monoclonal Antibody Therapy: Patient-Reported Outcomes.采用单克隆抗体疗法治疗新冠病毒病：患者报告的结果
Cureus. 2022 Sep 16;14(9):e29247. doi: 10.7759/cureus.29247. eCollection 2022 Sep.
3
Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.通过 SARS-CoV-2 变异株时代的肾移植受者中 COVID-19 的结局：抗 SARS-CoV-2 单克隆抗体的作用。
Transpl Int. 2022 Oct 4;35:10721. doi: 10.3389/ti.2022.10721. eCollection 2022.
4
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?新冠疫情能否改善实体器官移植受者的管理？
Viruses. 2022 Aug 24;14(9):1860. doi: 10.3390/v14091860.
5
Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients.早期给予抗SARS-CoV-2单克隆抗体可预防肾移植患者发生重症新型冠状病毒肺炎。
Kidney Int Rep. 2022 Jun;7(6):1241-1247. doi: 10.1016/j.ekir.2022.03.020. Epub 2022 Mar 26.
6
Durable Protection after Anti-SARS-CoV-2 Monoclonal Antibody Therapy.抗SARS-CoV-2单克隆抗体治疗后的持久保护作用。
Kidney360. 2022 Jan 27;3(1):8-10. doi: 10.34067/KID.0007722021.
7
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.成功早期使用抗 SARS-CoV-2 单克隆中和抗体治疗 SARS-CoV-2 感染的血液病患者：一项捷克多中心经验。
Hematol Oncol. 2022 Apr;40(2):280-286. doi: 10.1002/hon.2974. Epub 2022 Feb 17.
8
COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.新型冠状病毒肺炎与实体器官移植：抗严重急性呼吸综合征冠状病毒2单克隆抗体的作用
Curr Transplant Rep. 2022;9(1):26-34. doi: 10.1007/s40472-022-00357-2. Epub 2022 Jan 15.
9
The Role of HLA Antigens and Steroid Dose on the Course of COVID-19 of Patients After Kidney Transplantation.HLA抗原和类固醇剂量对肾移植术后COVID-19患者病程的影响
Front Med (Lausanne). 2021 Nov 1;8:730156. doi: 10.3389/fmed.2021.730156. eCollection 2021.
10
Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region.巴瑞替尼单抗联合etesevimab早期给药可增加COVID-19治疗的益处：利古里亚地区的真实世界经验
J Clin Med. 2021 Oct 13;10(20):4682. doi: 10.3390/jcm10204682.
本文引用的文献
1
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.Covid-19 住院患者的中和单克隆抗体。
N Engl J Med. 2021 Mar 11;384(10):905-914. doi: 10.1056/NEJMoa2033130. Epub 2020 Dec 22.
2
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.SARS-CoV-2 中和抗体 LY-CoV555 治疗门诊新冠患者的疗效。
N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.
3
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.COVID-19 于实体器官移植受者：来自美国震中地区的初步报告。
Am J Transplant. 2020 Jul;20(7):1800-1808. doi: 10.1111/ajt.15941. Epub 2020 May 10.
Zotero 插件